Atlas Capital Advisors LLC Reduces Holdings in DaVita Inc. (NYSE:DVA)

Atlas Capital Advisors LLC lowered its stake in DaVita Inc. (NYSE:DVA) by 14.3% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,361 shares of the company’s stock after selling 893 shares during the quarter. Atlas Capital Advisors LLC’s holdings in DaVita were worth $743,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Blue Trust Inc. boosted its stake in shares of DaVita by 58.6% during the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after acquiring an additional 78 shares during the last quarter. Wedmont Private Capital grew its holdings in shares of DaVita by 6.0% during the second quarter. Wedmont Private Capital now owns 1,701 shares of the company’s stock worth $241,000 after buying an additional 96 shares in the last quarter. First Trust Direct Indexing L.P. raised its position in shares of DaVita by 3.9% in the first quarter. First Trust Direct Indexing L.P. now owns 2,590 shares of the company’s stock valued at $358,000 after buying an additional 98 shares during the last quarter. Quent Capital LLC boosted its position in DaVita by 21.0% during the first quarter. Quent Capital LLC now owns 581 shares of the company’s stock worth $80,000 after acquiring an additional 101 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in DaVita by 18.8% in the 1st quarter. GAMMA Investing LLC now owns 657 shares of the company’s stock worth $91,000 after acquiring an additional 104 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Price Performance

DaVita stock opened at $150.92 on Friday. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. The firm has a market capitalization of $13.24 billion, a P/E ratio of 17.15, a PEG ratio of 0.89 and a beta of 0.87. The firm has a fifty day moving average of $142.50 and a 200-day moving average of $137.65. DaVita Inc. has a 52-week low of $71.51 and a 52-week high of $156.44.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.47 by $0.12. The company had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.15 billion. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.08 earnings per share. As a group, analysts predict that DaVita Inc. will post 9.99 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on DVA. Barclays raised their price objective on DaVita from $133.00 to $150.00 and gave the stock an “equal weight” rating in a report on Monday, May 6th. UBS Group raised their target price on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. StockNews.com lowered shares of DaVita from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 8th. Truist Financial lifted their price target on shares of DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a report on Tuesday, August 20th. Finally, TD Cowen upped their price objective on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, DaVita currently has an average rating of “Hold” and a consensus target price of $157.00.

Insider Buying and Selling at DaVita

In related news, insider Kathleen Alyce Waters sold 7,857 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the transaction, the insider now owns 83,011 shares in the company, valued at $12,137,038.31. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other DaVita news, COO Michael David Staffieri sold 9,539 shares of the firm’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the completion of the transaction, the chief operating officer now directly owns 241,945 shares of the company’s stock, valued at approximately $36,299,008.35. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares in the company, valued at approximately $12,137,038.31. The disclosure for this sale can be found here. Insiders sold a total of 113,601 shares of company stock valued at $17,525,449 in the last ninety days. Insiders own 2.00% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.